Loading organizations...
Itamar Medical has raised $28.0M across 1 funding round.
Key people at Itamar Medical.
Itamar Medical has raised $28.0M in total across 1 funding round.
Itamar Medical, based in Caesarea, Israel, specialized in developing and selling WatchPAT home sleep apnea testing devices for the non-invasive diagnosis of sleep disorders, particularly within cardiac patient care pathways. The company, which had approximately 280 employees prior to its acquisition, focused on diagnostic testing and management programs. In 2021, Itamar Medical was acquired by ZOLL Medical, a subsidiary of Asahi Kasei, for $538 million. Former President and CEO Gilad Glick led the company through significant growth and product development, including receiving FDA clearance in 2016 to expand WatchPAT's indication for sleep apnea diagnosis to ages 12 and above. Itamar Medical was founded in 1997 by Giora Yaron. Its business model centers on development, manufacture, and sale of WatchPAT products for medical diagnosis.
Itamar Medical has raised $28.0M in total across 1 funding round.
Itamar Medical's investors include 305 Ventures, Chemi, Cubit Investments Ltd, Mars Growth Capital, Ping An Ventures, Spark Capital, Viola Ventures, Ofer Adler, Rafi Gidron.
Key people at Itamar Medical.
Itamar Medical has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series U in August 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2015 | $28M Series U | — | 305 Ventures, Chemi, Cubit Investments LTD, Mars Growth Capital, Ping AN Ventures, Spark Capital, Viola Ventures, Ofer Adler, Rafi Gidron | Announced |
Itamar Medical is a medical device company specializing in non-invasive diagnostics for sleep apnea and related cardiovascular risks, primarily through its flagship WatchPAT home sleep apnea testing (HSAT) devices.[1][2][3] Acquired by ZOLL Medical Corporation in 2021, it now operates as ZOLL Itamar, serving patients, cardiologists, and sleep professionals by addressing undiagnosed sleep apnea—a condition affecting ~25% of adults and 60% of cardiovascular patients—with ~98% accurate, FDA-approved wearable tests that measure peripheral arterial tonometry (PAT) for apnea events, arrhythmia detection, and more.[2][3][4][5] Its growth includes global expansion, a 2020 SleepTech award, and innovative programs like direct-to-patient testing and eco-friendly device recycling, enhancing access amid rising demand for at-home diagnostics.[1][3][7]
Founded in 1995 (with some sources noting 1997) in Caesarea, Israel, Itamar Medical emerged from founders' work on vascular assessment devices, inspired by Itamar Yaron—a brother of a founder killed heroically in the Yom Kippur War and awarded Israel's Medal of Courage.[1][2] Early innovations included the EndoPAT for early heart disease detection and WatchPAT for sleep disorders, shifting focus to respiratory sleep apnea amid growing awareness of its cardiovascular links.[1] Pivotal moments: 2007 IPO on Tel Aviv Stock Exchange and Nasdaq; 2011 India entry; 2012 Russia distribution; $40M Nasdaq raise and SleepTech award in 2020; full acquisition by ZOLL in 2021, delisting its stock and integrating into cardiac care ecosystems.[1]
Itamar rides the exploding demand for home-based, AI-enhanced sleep diagnostics amid a global sleep apnea market projected to grow with rising obesity, aging populations, and post-pandemic telehealth adoption—25% adult prevalence underscores millions undiagnosed, fueling cardiovascular crises.[3][5] Timing aligns with cardiac-sleep convergence: studies link untreated apnea to heart failure, bradycardia, and atrial issues, positioning WatchPAT as a bridge for cardiologists integrating HSAT into workflows.[1][6] Favorable forces include FDA approvals, insurer reimbursements for HSAT, and ZOLL's distribution muscle, influencing ecosystems by mainstreaming non-invasive PAT over lab polysomnography, accelerating diagnosis-to-treatment pipelines and reducing healthcare burdens.[2][3]
Post-acquisition, ZOLL Itamar will likely scale WatchPAT globally via expanded direct programs, AI-driven PAT analytics, and deeper cardiology embeds—doubling test capacities signals robust momentum.[3][6] Trends like wearable health tech, value-based care, and apnea-cardio research will propel it, potentially evolving into full-spectrum cardio-sleep platforms influencing preventive medicine. As a ZOLL pioneer, its trajectory ties back to transforming sleep apnea from overlooked killer to routinely managed risk, democratizing diagnostics for healthier hearts worldwide.[1][2][5]
